Seattle Genetics (SGEN) Announces FDA Granted Breakthrough Therapy Designation to ADCETRIS for Frontline Peripheral T-Cell Lymphomas
Go back to Seattle Genetics (SGEN) Announces FDA Granted Breakthrough Therapy Designation to ADCETRIS for Frontline Peripheral T-Cell LymphomasSeattle Genetics Inc /wa (NASDAQ: SGEN) | Delayed: 228.74 --0 (-0%) | |||||
---|---|---|---|---|---|---|
Previous Close | $228.74 | 52 Week High | $75.36 | |||
Open | $228.74 | 52 Week Low | $26.02 | |||
Day High | $228.74 | P/E | N/A | |||
Day Low | $228.74 | EPS | $-0.51 | |||
Volume | 4 |